Patrick T. Kurnia

Patrick T. Kurnia

Auto-generated profile, based on publicly available information

Patrick T. Kurnia

Broad Institute 4 , Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026
Verified
Other
Open access
ESElia Seguí
Elia Seguí
JZJorge Gomez Tejeda Zañudo
Jorge Gomez Tejeda Zañudo
NGNoah Graham
Noah Graham
PKPatrick T. Kurnia
Patrick T. Kurnia
APAndrea N. Perry
Andrea N. Perry
JLJosé Pablo Leone
José Pablo Leone
Purpose:Human epidermal growth factor receptor 2 (HER2)–positive breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, combined with trastuzumab. Patients and Methods:Eligible patients had active/progressive HER2+ BCBM and could have received prior therapies; leptomeningeal disease was excluded. The trial included a safety run-in to determine the recommended phase II dose (RP2D), followed by expansion cohorts. The primary endpoint was confirmed central nervous system (CNS) objective response rate (ORR) per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria at the RP2D. Paired plasma and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was analyzed using ultralow-pass whole-genome sequencing (ULP-WGS) and whole-exome sequencing (WES). Results:Seventeen patients were treated (median age, 44 years; median 5 prior therapy lines). Paxalisib 30 mg daily plus trastuzumab was established as the RP2D. Among 12 patients treated at the RP2D, no confirmed CNS responses occurred [CNS ORR, 0%; 95% confidence interval (CI), 0%–26.5%], and the study closed for futility. The median overall survival (OS) was 16.5 months. Treatment was feasible, with a safety profile consistent with PI3K/mTOR inhibition. Exploratory ctDNA analyses showed higher tumor fraction (TF) in CSF than plasma, with longitudinal changes in CSF TF paralleling CNS tumor burden. Conclusions:Paxalisib combined with trastuzumab was feasible but did not meet the primary endpoint of CNS ORR in heavily pretreated HER2+ BCBM. Exploratory findings suggest that CSF-derived ctDNA may better capture tumor genomics and treatment response than plasma ctDNA in HER2+ BCBM. Significance:The brain-penetrant dual PI3K/mTOR inhibitor paxalisib plus trastuzumab showed minimal activity in heavily pretreated HER2+ BCBM. Paired liquid biopsy analyses demonstrated that CSF-derived ctDNA may better reflect tumor genomics and treatment response than plasma, supporting CSF for translational studies in this setting. Trial Registration:ClinicalTrials.gov identifier: NCT03765983.

6 November 2026
Verified
Other
Open access
ESElia Seguí
Elia Seguí
JZJorge Gomez Tejeda Zañudo
Jorge Gomez Tejeda Zañudo
NGNoah Graham
Noah Graham
PKPatrick T. Kurnia
Patrick T. Kurnia
APAndrea N. Perry
Andrea N. Perry
JLJosé Pablo Leone
José Pablo Leone
Efficacy outcomes by RANO-BM and RECIST v1.1 in the primary analysis populationa treated at paxalisib 30 mg (n = 12).



6 November 2026
Verified
Other
Open access
ESElia Seguí
Elia Seguí
JZJorge Gomez Tejeda Zañudo
Jorge Gomez Tejeda Zañudo
NGNoah Graham
Noah Graham
PKPatrick T. Kurnia
Patrick T. Kurnia
APAndrea N. Perry
Andrea N. Perry
JLJosé Pablo Leone
José Pablo Leone
TF dynamics, clonal evolution, and phylogenetic analyses from plasma and CSF and plasma ctDNA. A, Median TF estimated by ULP-WGS in paired plasma and CSF samples at baseline and cycle 2 day 1 (C2D1). TF was consistently higher in CSF than plasma at both timepoints (n = 10 samples/5 patients). B, Longitudinal CSF TF dynamics in individual patients relative to changes in CNS target lesions assessed by RANO-BM criteria (n = 10 samples/5 patients). Patients with declining CSF TF exhibited reductions in CNS tumor burden, whereas increasing TF was associated with lesion growth or nonevaluable disease. The asterisk (*) identifies the patient who derived clinical benefit. C, Clonal evolution in CSF ctDNA from patient #5, showing changes in cancer cell fraction (|ΔCCF| >0.20) between timepoints. D, Phylogenetic reconstruction for patient #4 based on WES of plasma and CSF ctDNA, illustrating shared truncal mutations and CSF subclones present at low clonality in plasma. CB, clinical benefit.

6 November 2026
Verified
Other
Open access
ESElia Seguí
Elia Seguí
JZJorge Gomez Tejeda Zañudo
Jorge Gomez Tejeda Zañudo
NGNoah Graham
Noah Graham
PKPatrick T. Kurnia
Patrick T. Kurnia
APAndrea N. Perry
Andrea N. Perry
JLJosé Pablo Leone
José Pablo Leone
Longitudinal plasma tumor fraction (TF) dynamics in individual patients relative to changes in CNS target lesions assessed by RANO-BM criteria.